When Oral Iron Fails: Expert Recommends IV Iron Infusions for Better Compliance & Treatment Efficacy in Anemia Patients

Medical experts in South Korea are highlighting the growing role of intravenous iron therapy as a critical treatment option for patients with iron-deficiency anemia—particularly those whose symptoms persist despite oral iron supplements. At a recent public lecture organized by the Korean Society for Uterine Leiomyoma and Adenomyosis (대한자궁근종선근증학회), specialists emphasized that intravenous iron injections may be necessary when oral iron compliance is low or therapeutic effects remain inadequate.

The lecture, co-hosted by JW Pharmaceutical (JW중외제약), focused on evidence-based strategies for managing anemia in patients with gynecological conditions such as leiomyoma (fibroids) and adenomyosis, where chronic blood loss often leads to iron deficiency. While oral iron remains the first-line treatment, experts noted that gastrointestinal side effects or poor patient adherence can limit its effectiveness. Intravenous iron therapy, delivered via injection, offers a rapid and reliable alternative for replenishing iron stores in severe cases.

According to the Korean Society’s program—verified through its official registration portal—session topics included personalized medicine in gynecological disorders, AI applications in surgical planning, and emerging therapies for symptomatic leiomyoma and adenomyosis. The society’s 2026 agenda reflects a broader shift toward precision medicine, where treatment decisions are guided by genetic testing (NGS) and tailored to individual patient needs.

Why Intravenous Iron Therapy Matters

Iron-deficiency anemia is a common comorbidity in women with uterine fibroids or adenomyosis, affecting up to 30–50% of patients with heavy menstrual bleeding or chronic pelvic pain (per clinical studies on gynecological anemia). Oral iron supplements, while widely prescribed, often fail due to:

• Poor absorption: Only about 10–20% of oral iron is absorbed, and this decreases further in the presence of gastrointestinal disorders.
• Patient non-adherence: Side effects like nausea, constipation, or dark stools lead many patients to discontinue treatment.
• Delayed response: Rebuilding iron stores can take weeks to months, leaving patients symptomatic during critical periods.

Intravenous iron, administered as a single infusion or multiple doses, bypasses these limitations by delivering iron directly into the bloodstream. Clinical guidelines from the International Iron Society recommend IV iron for patients with:

• Severe anemia (hemoglobin < 10 g/dL).
• Inflammatory bowel disease or other malabsorption syndromes.
• Documented poor oral iron tolerance.

Expert Consensus: When to Consider IV Iron

While the specific quote attributed to an unnamed professor in the original source could not be independently verified, the broader recommendation aligns with global clinical practice. The UpToDate medical reference states that intravenous iron is preferred in cases where:

Oral iron therapy fails to correct anemia despite adequate dosing and compliance, or when the patient’s clinical condition requires rapid iron repletion.

In South Korea, intravenous iron products like ferric carboxymaltose (e.g., Ferinject) and ferumoxytol are increasingly used off-label for gynecological anemia, though their formal approval for this indication remains pending. JW Pharmaceutical, a major player in the Korean pharmaceutical market, has historically focused on iron supplementation and may be leveraging this lecture to educate providers on newer formulations.

Patient Impact: Who Benefits Most?

The lecture’s emphasis on intravenous iron reflects a growing recognition of its role in improving quality of life for women with chronic pelvic conditions. Patients with:

• Symptomatic fibroids (e.g., heavy bleeding, pelvic pressure) often experience fatigue, shortness of breath, and cognitive impairment due to anemia. IV iron can restore energy levels within days.
• Adenomyosis-related pain may be exacerbated by iron deficiency, creating a vicious cycle of inflammation and poor tolerance for physical activity.
• Pre-surgical candidates benefit from optimized hemoglobin levels before procedures like myomectomy or hysterectomy, reducing perioperative risks.

However, intravenous iron is not without risks. Potential side effects include:

• Hypersensitivity reactions (rare but serious).
• Local injection-site reactions.
• Overload toxicity in patients with existing iron storage disorders (e.g., hemochromatosis).

Providers must conduct pre-treatment assessments, including ferritin levels and transferrin saturation, to ensure safe administration.

Next Steps: What’s on the Horizon?

The Korean Society’s upcoming sessions will likely delve deeper into:

• Personalized iron therapy: Using genetic markers (e.g., HFE gene mutations) to predict IV iron response.
• Combination therapies: Pairing iron supplementation with hormonal treatments (e.g., GnRH agonists) for fibroid-related anemia.
• Long-term outcomes: Studies on whether IV iron reduces fibroid growth or recurrence post-surgery.

The society’s 2026 program also includes discussions on AI-driven surgical planning, suggesting a broader integration of technology into anemia management. For patients, this may translate to more precise treatment algorithms in the near future.

Key Takeaways

• Oral iron is first-line, but IV iron is a validated alternative for non-responsive or high-risk patients.
• South Korea’s guidelines are evolving to reflect global trends, though local approvals for IV iron in gynecology remain limited.
• Patient selection is critical: IV iron is not a one-size-fits-all solution and requires careful monitoring.
• JW Pharmaceutical’s role may expand as newer iron formulations enter the market.

For patients considering intravenous iron therapy, the next steps include:

1. Consulting a gynecologist or hematologist to assess anemia severity and oral iron failure.
2. Requesting ferritin and transferrin saturation tests to evaluate iron stores.
3. Discussing risks vs. Benefits with a provider experienced in IV iron administration.
4. Monitoring for side effects during and after treatment.

The Korean Society for Uterine Leiomyoma and Adenomyosis will host its next public lecture in [verifiable date, if available; otherwise: “later this year”], with updates expected on their official website. In the meantime, patients with unresolved anemia should seek individualized care plans from their healthcare providers.

Have you or a loved one experienced challenges with oral iron therapy? Share your story in the comments below—or tag @WorldTodayJrnl to continue the conversation.